Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep990 | Pituitary - Clinical | ECE2017

Somatostatin analogs in the treatment of acromegaly: single centre experience

Abraitiene Agne , Aleknaite Aiste , Zelnyte Gintare

Introduction: The purpose of this study was to evaluate effectiveness of somatostatin analog (SSA) treatment in patients with acromegaly.Methods: The study involved retrospective data collection from charts of 29 patients with acromegaly who received medical therapy at Vilnius University Hospital Santariskiu klinikos in 2016.Results: Patient population consisted of 10 males (34.5%) and 19 females (65.5%), mean age 58±26 years....

ea0056ep100 | Pituitary and Neuroendocrinology | ECE2018

Characteristics of clinical and morphological features of functioning and nonfunctioning pituitary adenomasand disorders commonly associated with them

Tulabaite Kotryna , Splitaite Anna , Abraitiene Agne , Zelnyte Gintare

Background: The prevalence of pituitary adenomas (PAs) is increasing as the development of imaging techniques. The objective of this study is to assess the clinical and morphological features of non-functioning, prolactin, and grown-hormone secreting pituitary adenomas and to analyze the accompanying diseases of each condition.Methods: A retrospective analysis of the clinical records of patients with non-functioning (NFPA), prolactin (PRL+) or grown horm...

ea0056ep101 | Pituitary and Neuroendocrinology | ECE2018

Prolactinoma management: factors that might predict remission of the disease after 12 months of treatment

Splitaite Anna , Tulabaite Kotryna , Abraitiene Agne , Zelnyte Gintare

Background: Dopamine agonists (DAs) are the primary treatment for both microprolactinomas and macroprolactinomas. Two medications are FDA approved for the medical treatment of prolactinomas: cabergoline and bromocriptine. Although bromocriptine is deemed a secondary option after cabergoline, its lower cost may be a consideration for some patients. The purpose of this study is to analyze patients treated with different DAs during 12 months period and to identify the unchangeabl...